In a large clinical trial, treatment with pembrolizumab (Keytruda) after surgery helped people with kidney cancer live longer than those who got a placebo and standard monitoring. The findings mark the first time an adjuvant treatment for kidney cancer has improved survival.
People with cancer who have depression, pain, and fatigue are often referred to providers for treatment and must follow up to make an appointment. A recent clinical trial showed that integrating the assessment and treatment of symptoms as part of routine care may help them better manage these problems.
The Food and Drug Administration (FDA) has approved alectinib (Alecensa) given after surgery for people with lung cancer who have ALK-positive tumors. In a clinical trial comparing alectinib with chemotherapy, alectinib helped people live longer without their cancer returning.
Trastuzumab deruxtecan (Enhertu) can now be used to treat any advanced solid cancer that produces high levels of the protein HER2 (HER2-positive tumors). FDA’s accelerated approval was based on findings from three clinical trials.
Clinical Trials Information for Patients and Caregivers
This phase 2 trial will test the ability of a radiotracer called 18F-fluciclovine to detect a relapse of multiple myeloma in people whose cancer is in remission. A radiotracer is a substance injected into the blood during imaging scans. Doctors want to see how the new radiotracer compares with the one currently used.
This clinical trial will test a combination of gene-modified tumor-infiltrating lymphocytes (TIL) and a vaccine designed to target cancer-specific proteins in people with cancer that has spread. Both the TIL therapy and vaccine target the same proteins. Doctors want to see if combining TIL therapy and a targeted vaccine is safe and how well it works to shrink tumors.
This phase 2 clinical trial will test whether adding metformin, a drug commonly used to treat diabetes, to standard non-surgical treatment with megestrol acetate will help prevent endometrial intraepithelial neoplasia from turning into endometrial cancer.
